Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 3
2010 1
2011 1
2012 4
2013 4
2014 7
2015 2
2016 9
2017 4
2018 8
2019 12
2020 12
2021 15
2022 9
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M. Frank S, et al. Among authors: jimenez shahed j. Neurol Ther. 2024 Apr 1. doi: 10.1007/s40120-024-00600-1. Online ahead of print. Neurol Ther. 2024. PMID: 38557959
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Harary E, Alexander J, Barkay H, Gordon MF. Jankovic J, et al. Among authors: jimenez shahed j. Mov Disord Clin Pract. 2023 Aug 24;10(9):1388-1398. doi: 10.1002/mdc3.13849. eCollection 2023 Sep. Mov Disord Clin Pract. 2023. PMID: 37772282 Free PMC article.
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum: Revelations from the MANAGE-PD validation cohort.
Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-Shahed J, Metz S, Alobaidi A, Yan CH, Kukreja P, Parra JC, Zamudio J, Onuk K, Wright J, Antonini A. Fernandez HH, et al. Among authors: jimenez shahed j. Parkinsonism Relat Disord. 2023 Nov;116:105514. doi: 10.1016/j.parkreldis.2023.105514. Epub 2023 Jul 6. Parkinsonism Relat Disord. 2023. PMID: 37563079 Free article.
Interactive mobile application for Parkinson's disease deep brain stimulation (MAP DBS): An open-label, multicenter, randomized, controlled clinical trial.
Duffley G, Szabo A, Lutz BJ, Mahoney-Rafferty EC, Hess CW, Ramirez-Zamora A, Zeilman P, Foote KD, Chiu S, Pourfar MH, Goas Cnp C, Wood JL, Haq IU, Siddiqui MS, Afshari M, Heiry M, Choi J, Volz M, Ostrem JL, San Luciano M, Niemann N, Billnitzer A, Savitt D, Tarakad A, Jimenez-Shahed J, Aquino CC, Okun MS, Butson CR. Duffley G, et al. Among authors: jimenez shahed j. Parkinsonism Relat Disord. 2023 Apr;109:105346. doi: 10.1016/j.parkreldis.2023.105346. Epub 2023 Mar 16. Parkinsonism Relat Disord. 2023. PMID: 36966051 Clinical Trial.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
90 results